• Deep Learning for iPSC-CM Cardiotoxicity Screening

  2026-09-29

  The eLife study developed a deep-learning and high-content imaging workflow for detecting cardiotoxic phenotypes in human iPSC-derived cardiomyocytes. Its target-agnostic scoring strategy identified liabilities across ion-channel, kinase, DNA-intercalating, and other compound classes, supporting earlier safety decisions in drug discovery.

• SLC25A1 Links Mitochondria to PD-L1 and IFN-I

  2026-09-29

  This bioRxiv preprint identifies SLC25A1 as a tumor-intrinsic regulator connecting mitochondrial signaling, type I interferon activity, and PD-L1 protein stability. Its findings suggest that SLC25A1 may simultaneously promote immune evasion and create a context-dependent vulnerability to PD-L1 blockade, although validation in peer-reviewed and clinically representative systems remains necessary.

• G-1 Selective GPR30 Agonist: Research Workflows

  2026-09-28

  Build cleaner estrogen-signaling experiments with G-1, from rapid calcium and PIP3 assays to breast cancer migration, cardiovascular, and spinal pain models. Its GPR30 preference helps separate non-classical estrogen signaling from ERα/ERβ-driven effects while practical formulation guidance reduces avoidable assay variability.

• Spirocyclic POM Analogues Target MmpL3 in TB

  2026-09-28

  This study describes spirocyclic phenyl oxazole methyl (POM) analogues as a new anti-tuberculosis series and identifies compound 5c as a potent inhibitor of drug-susceptible and resistant Mycobacterium tuberculosis isolates. Mutant-generation analysis implicates MmpL3 as the target, while docking and early pharmacology support further investigation without establishing clinical efficacy or direct target engagement.

• EdU Imaging Kits (Cy5) for Myogenesis Studies

  2026-09-27

  Separate S-phase activity from differentiation outcomes in myoblast experiments with a sensitive EdU readout that preserves cell morphology without DNA denaturation. This workflow-oriented guide shows how to pair Cy5 labeling with mitochondrial-clearance studies while avoiding the common mistake of treating proliferation as a direct measure of myogenic maturation.

• G-1 and the Translational Logic of GPR30

  2026-09-26

  G-1 offers a selective way to investigate rapid GPR30 signaling. This article connects receptor pharmacology with immune, cardiovascular, and cancer research while outlining practical controls and translational limits.

• Pepstatin A Workflows for Protease Research

  2026-09-25

  Pepstatin A supports targeted studies of aspartic proteases, from enzyme assays and osteoclast differentiation to HIV protein processing. This guide pairs practical setup and troubleshooting advice with a clear boundary between established uses and questions raised by new macrophage-infection research.

• Anlotinib Hydrochloride: From Target to Tumor

  2026-09-25

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose endothelial effects provide a framework for studying tumor angiogenesis. This article connects receptor-level assays with a rare-tumor case report while distinguishing translational clues from clinical proof.

• Dextrose (D-glucose) in Metabolic Research

  2026-09-24

  Dextrose (D-glucose) is a defined glucose substrate for glucose metabolism research, including studies of hypoxia and nutrient competition. Product specifications for A8406 report 98.00% purity, solid storage at −20°C, and solvent-specific solubility values; they do not establish a universal cell-culture dose or treatment effect.

• NME3 Links Mitochondrial Fusion to ccRCC Progression

  2026-09-24

  The study identifies NME3 as a promoter of clear cell renal cell carcinoma (ccRCC) progression, linking its interaction with MFN1/2 to mitochondrial fusion, oxidative phosphorylation, and suppression of PINK1/Parkin-associated mitophagy. It also reports that reducing NME3 increases sensitivity to sorafenib and sunitinib in experimental models, suggesting a potential connection between mitochondrial state and tyrosine kinase inhibitor response.

• Hematoxylin B3671: Practical Nuclear Staining Guide

  2026-09-23

  Hematoxylin (B3671) is a solid nuclear stain for visualizing cell nuclei in established histological and cytological workflows, including hematoxylin and eosin staining. It is a research reagent, not a complete staining kit, and is not intended for diagnostic, clinical, or medical use.

• G-1 and GPR30: From Receptor Biology to Pain Circuits

  2026-09-23

  Explore how G-1, a selective GPR30 agonist, can be used to interrogate rapid estrogen signaling across pain, cardiovascular, and cancer models. This article connects receptor pharmacology with circuit-level assay design while clarifying what current neuropathic-pain evidence does—and does not—demonstrate.

• Oncostatin M as a Translational Cytokine Lever

  2026-09-22

  A thought-leadership guide to using rh-Oncostatin M as a controlled inflammatory perturbation, with practical assay design, product-selection criteria, and a cautious bridge to lysosomal cell-death research in renal cancer.

• 2,2,2-Trichloroethanol for Protein Analysis

  2026-09-22

  Use 2,2,2-Trichloroethanol as a practical in-gel protein visualization and sample-quality tool, then connect molecular readouts with orthogonal neurobiology endpoints. This guide distinguishes validated product specifications from workflow starting points and explains how the reagent can complement, but not replace, DAT imaging and histology.

• IWP-L6: Precision Control of Wnt Signaling

  2026-09-21

  A mechanistic and translational guide to using IWP-L6 as a Porcupine inhibitor, connecting Porcn-dependent Wnt ligand activation with osteogenic metabolism, assay design, and evidence-based research strategy.

8014 records 1/535 page Next 12345 下5页 Last page